81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...

NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...

Just like old wine in a new bottle, an old meme has gotten an analog horror makeover with the SCP-67 kid. The trend has gone viral on TikTok with several versions showing the character with his mouth ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...

SCD seeks total returns with a primary focus on income, investing globally in companies with strong fundamentals and clear market advantages. The fund uses leverage to enhance returns, with interest ...

Sun Pharmaceutical Industries Limited announced top-line results from the phase 2 clinical trial evaluating the safety and efficacy of SCD-044 (a novel, orally bioavailable sphingosine-1- phosphate ...

Sickle cell disease (SCD) altered CD8+ T-cell chromatin architecture, triggering ferroptosis and weakening antitumor immunity. Hydrogen sulfide (H2S) treatment restored chromatin interactions and ...

SCD, a global leader in defense technology specializing in the development and manufacture of a wide range of cooled and uncooled infrared detectors and high-power laser diodes, announces significant ...

SICKLE cell disease (SCD) is common throughout much of sub-Saharan Africa, affecting up to 3 per cent of births in some parts of the continent TANZANIA: SICKLE Cell Disease (SCD) remains a significant ...

The one million plus visitors to the four day Tall Ships Festival which took place at Dublin Docks in August 2012 were kept safe with the help of a crowd control video survei... Le Meurice Hotel ...